Letter by Robinson Regarding Articles, “Bringing Back Targets to ‘IMPROVE’ Atherosclerotic Cardiovascular Disease Outcomes: The Duel for Dual Goals; Are Two Targets Better Than One?” and “Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT”
2015 ◽
Vol 132
(13)
◽
pp. 1224-1233
◽
2017 ◽
Vol 20
(3)
◽
pp. 654-659
◽
2009 ◽
Vol 53
(11)
◽
pp. 931-935
◽
2012 ◽
Vol 19
(11)
◽
pp. 1027-1034
◽
2013 ◽
Vol 7
(4)
◽
pp. 292-303
◽